Tag Archives: Regulatory

Less is More: HHS Austerity Care

By Tom Norton As the US Department of Health and Human Services (HHS) circles around the elements of health care that will actually be included in our new “Essential Health Benefits” (EHB), one aspect of the EHB offering has caused a tremendous stir among dozens of health groups.  Their collective concern is focused on the pharmaceutical [...]
Posted in Guest Blog, Legal, Regulatory, compliance, healthcare | Also tagged , , , , , , , | Leave a comment

Government-Funded Research: Is It That Different?

In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research.” The report was ordered by President Obama following an October 2010 revelation that the US Public Health Service supported unethical research in Guatemala from 1946 to 1948 that involved intentionally exposing thousands of Guatemalans to sexually transmitted diseases [...]
Posted in Guest Blog, R&D, Regulatory, Safety | Also tagged , , | Leave a comment

Compliance Top Driver of Change, Survey Says

Last year, only two percent of the respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption, and six percent said regulatory and compliance was a primary driver of pharmaceutical business model or process change. A lot can happen in a year.
Posted in Market Access, Strategy, compliance | Also tagged , , | Leave a comment

So, Where Are We with ACOs?

Tom Norton gets to grips with what an Accountable Care Organization is … and what it is not. Sixteen months into the new Healthcare Reform law, many continue to wonder about the status one of the most confused aspects of the new HCR — the elusive Accountable Care Organization, or ACO. And why are ACOs viewed [...]
Posted in Guest Blog, Regulatory | Also tagged , , , , | 2 Comments

Bad Ad: One Year of Fear

FDA’s Bad Ad program, launched in May of 2010, resulted in some 328 reports of potentially untruthful or misleading promotion, a handful of Warning Letters, and several Untitled Letters. But the single most effective tool in the Bad Ad program’s toolkit, according to Arnie Friede, principal at Arnold I. Friede & Associates, and a former associate [...]
Posted in Advertising, Corporate Responsibility, FDA, Legal, Marketing, Regulatory, compliance | Also tagged , , | Leave a comment